<DOC>
	<DOC>NCT02799498</DOC>
	<brief_summary>The purpose of the study is to compare Pharmacokinetics of liquid etanercept that is administered to healthy subjects aged 18-55 by an auto-injector device and manual injection (each subject received both injections).</brief_summary>
	<brief_title>Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection</brief_title>
	<detailed_description>This single-center, randomized, open-label, 2-period, 2-sequence, 2-treatment, crossover study in healthy men and women compared the pharmacokinetics (PK) and safety profiles of two 50-mg subcutaneous (SC) injections of etanercept liquid (in a 1.0-mL prefilled syringe): (1) using a disposable auto-injector device, and (2) using a standard manual injection. Each subject received both injections in the abdomen, separated by a washout period of 28 days.</detailed_description>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Healty men and women Aged 1855 years at time of screening BMI 1831 kg/m2 inclusive Free of any clinically significant disease Willing to reside in research facility 4 consecutive nights 2 times and to attend follow up visits Willing to sign consent Negative HIV, hepatitis B and C, and urine pregnancy tests Unstable medical condition (hospitalized within 30 days, myocardial infarction or major surgery within 6 months, or seizure within 12 months of study day 1) Current active infecton, history of infections, or condition which may predispose infection (such as diabetes) Clinically significant abnormality in laboratory samples done while screening history of tuberculosis donated blood within 30 days of screening Use of prescription or overthecounter medication during the study/ History of smoking or use of tobacco within 30 days of screening Positive urine scree for alcohol or drugs of abuse at screening or the day prior to dosing Unwilling to pracitce contraception for the duration ot the study Any other condition which could interfere with obtaining data required by the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>etanercept</keyword>
	<keyword>healthy subject</keyword>
	<keyword>open-label</keyword>
	<keyword>randomized</keyword>
	<keyword>PK</keyword>
	<keyword>auto-injection</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>